Associated Papers
Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.
van Tienen LM et al.
Cell Chemical Biology, 2026
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.
Motta L et al.
Cancers, 2025
Denitrogenative Alkylation of K-Ras(G12D) Inhibits Oncogenic Signaling in Cancer Cells.
Zheng Q et al.
Journal of the American Chemical Society, 2025
Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia.
Yang J et al.
Bioorganic Chemistry, 2025
Regional and Gender-Based Distribution of KRAS Mutations in Metastatic Colorectal Cancer Patients in Turkey: An Observational Study.
Ilhan N et al.
Medicina (kaunas, Lithuania), 2025
The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients.
Abrehdari-Tafreshi Z et al.
Biochemical Genetics, 2024
Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.
Mosaferi Z et al.
Journal of Gastrointestinal Cancer, 2024
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.
Bando H et al.
Cancer Science, 2024
Structural modifications and kinetic effects of KRAS interactions with HRAS and NRAS: an in silico comparative analysis of KRAS mutants.
Silverman I et al.
Frontiers in Molecular Biosciences, 2024
KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
Mirzapoor Abbasabadi Z et al.
Journal of Clinical Laboratory Analysis, 2023
Potential genetic biomarker of Saudi Arabian patients with colorectal cancer.
Younis NS et al.
European Review for Medical and Pharmacological Sciences, 2022
Ophthalmic manifestations in Costello syndrome caused by Ras pathway dysregulation during development.
Shankar SP et al.
Ophthalmic Genetics, 2022
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.
Malapelle U et al.
European Journal of Cancer (oxford, England : 1990), 2021
Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway.
Gillies TE et al.
Molecular Systems Biology, 2020
A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS Mutants.
Han CW et al.
Cancers, 2020
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C et al.
Haematologica, 2020
Comprehensive Analysis of PTEN in Primary Cutaneous Melanoma.
Němejcová K et al.
Folia Biologica, 2020
KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer.
Ergun Y et al.
Expert Review of Molecular Diagnostics, 2019
A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants.
Ticha I et al.
Scientific Reports, 2019
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H et al.
Ebiomedicine, 2019
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
Sakakibara K et al.
International Journal of Hematology, 2019
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Shaukat I et al.
Human Pathology, 2019
Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene.
Zhang Q et al.
Biomed Research International, 2018
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.
Jones RP et al.
British Journal of Cancer, 2017
Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
Jauhri M et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2017
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.
Lu S et al.
Chemical Society Reviews, 2016
K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
Li T et al.
Medical Oncology (northwood, London, England), 2016
Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer.
Nicoś M et al.
Clinical and Experimental Medicine, 2016
Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.
Clark DJ et al.
Theranostics, 2016
KRAS and BRAF Mutation Detection: Is Immunohistochemistry a Possible Alternative to Molecular Biology in Colorectal Cancer?
Piton N et al.
Gastroenterology Research and Practice, 2015
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.
Said R et al.
Oncotarget, 2014
Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.
Tong JH et al.
Cancer Biology & Therapy, 2014
Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G et al.
Clinical Lung Cancer, 2014
Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
Cushman-Vokoun AM et al.
Clinical Colorectal Cancer, 2013
The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer.
Ouerhani S et al.
Molecular Biology Reports, 2013
Characteristics of lung cancers harboring NRAS mutations.
Ohashi K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population.
Ozen F et al.
Genetic Testing and Molecular Biomarkers, 2013
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Janku F et al.
Cancer Research, 2013
Application of pyrosequencing technique for improved detection of K-Ras mutation in formalin-fixed and paraffin-embedded prostate carcinoma tissues in Chinese patients.
Sha J et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2012
HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.
Niihori T et al.
Journal of Human Genetics, 2011
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
Fumagalli D et al.
Bmc Cancer, 2010
Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.
Soung YH et al.
Virchows Archiv : an International Journal of Pathology, 2005
High BRAF mutation frequency does not characterize all melanocytic tumor types.
Saldanha G et al.
International Journal of Cancer, 2004
Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status.
Hsu J et al.
Clinical Pathology (thousand Oaks, Ventura County, Calif.), 0